Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions

Journal of Endocrinological Investigation

Volumn 21, Issue 2, 1998, Pages 115-121

  Gianotti, L ^a   Broglio, F ^a   Aimaretti, G ^a   Arvat, E ^a   Colombo, S ^b   Di Summa, M ^a   Gallioli, G ^b   Pittoni, G ^c   Sardo, E ^a   Stella, M ^d   Zanello, M ^e   Miola, C ^f   Ghigo, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d CTO HOSPITAL   (Italy)

^e BELLARIA HOSPITAL   (Italy)

^f PFIZER INC   (United States)

Author keywords

Catabolism; Critical illness; Growth hormone; IGF I

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ADULT; ANOREXIA NERVOSA; ARTICLE; BURN; CATABOLISM; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HEART SURGERY; HUMAN; HYPOPITUITARISM; INJURY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; SEPSIS;

EID: 18144450897     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350325     Document Type: Article

References (52)

1. Jenkins R.C., Ross R.J.M. The endocrinology of the critically ill. Curr. Opin. Endocrinol. Diab. 3: 138, 1996.
2. Dahn M.S., Lange M.P., Jacobs L.A. Insulinlike growth factor-I production is inhibited in human sepsis. Arch. Surg. 123: 1409, 1993.
3. Belcher H.J.C.R., Mercer D., Judkins K.C., Shalaby S., Wise S., Marks V., Tanner N.S.B. Biosynthetic human growth hormone in burned patients: a pilot study. Burns 15: 99, 1989.
4. Fleming R.Y.D., Rutan R.L., Jahoor F., Barrow R.E., Wolfe R.R., Herndon D.N. Effect of recombinant human growth hormone on catabolic hormones and free fatty acids following thermal injury. J. Trauma 323: 698, 1992.
5. Voerman H.J., Strack van Schijndel R.J.M., Groeveld A.B.J., de Boer H., Nauta J.P., van der Veen E.A., Thijis L.G. Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg., 216: 648, 1992.
6. Abribat T., Brazeau P., Davignon I., Garrel D.R. Insulin-like growth factor-I blood levels in severely burned patients: effects of time post injury, age of patient and severity of burn. Clin. Endocrinol. (Oxf.) 2: 583, 1993.
7. Ross R.J.M., Chew S.L. Acquired growth hormone resistance. Eur. J. Endocrinol. 132: 655, 1995.
8. Cotterill A.M., Mendel P., Holly J.M.P., Timmins C, Camacho-Hubner S.C., Hughes R.M.J., Ross W.F., Langford R.M. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clin. Endocrinol. (Oxf.) 44: 91, 1996.
9. Timmins A.C., Cotterill A.M., Cwylan Hughes S.C., Holly R.J.M., Blum W., Hinds C.J. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and-II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit. Care Med. 9: 1460, 1996.
10. Bentham J., Rodriguez-Arnao J., Ross R.J.M. Acquired growth hormone resistance in patients with hypercatabolism. Horm. Res. 40: 87, 1993.
11. Merimee T.J., Fineberg S.E. Dietary regulation of human growth hormone secretion. Metabolism 12: 1491, 1973.
12. Thissen J., Keteslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr. Rev. 15: 80, 1994.
13. Herndon D.N., Barrow R.E., Kunkle K.R., Broemeling L., Rutan L. Effects of recombinant human growth hormone on donor-site in severely burned children. Ann. Surg. 212: 424, 1990.
14. Ziegler T.R., Romeau J.L., Young L.S., Fong Y., Marano M., Lowry S.F., Wilmore D.W. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J. Clin. Endocrinol. Metab. 74: 865, 1992.
15. Byrne T.A., Morissey T.B., Gatzen C., Benfell K., Nattakom T.V., Scheltinga M.R., LeBoff M.S., Ziegler T.R., Wilmore D.W. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann. Surg. 218, 4: 400, 1993.
16. Mulligan K., Grunfeld C., Hellerstein M.K., Nees R.A., Schambelan M.S. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77: 956, 1993.
17. Wilmore D.W. Catabolic illness. N. Engl. J. Med. 10: 695, 1991.
18. Pichard C., Jolliet P., Chevrolet J.C., Romand J.A., Slosman D. Recombinant human growth hormone in chronic and acute respiratory insufficiency. Horm. Res. 46: 222, 1996.
19. Vara-Thorbeck R., Ruiz-Requena E., Guerrero-Fernandez J.A. Effects of human growth hormone on the catabolic state after surgical trauma. Horm. Res. 45: 55 1996.
20. Ross R., Miell J., Jones J., Matthews D., Preece M., Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin. Endocrinol. (Oxf.) 35: 47, 1991.
21. Nygren J., Sammann M., Malm M., Efendict S., Hall K., Brismar K., Ljungqvist O. Disturbed anabolic hormonal patterns in burned patients: the relation to glucagon. Clin. Endocrinol. (Oxf.) 43: 491, 1995.
22. Donaghy A., Ross R., Gimson A., Hughes S.C., Holly J., Williams R. Growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 21: 680, 1995.
23. Frost R.A., Fuhrer J., Steigbigel P., Mariuz P., Lang C.H., Gelato M.C. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin. Endocrinol. (Oxf.) 44: 501, 1996.
24. Van den Berghe G, de Zegher F., Lauwers P., Veldhuis J.D. Growth hormone secretion in critical illness: Effect of dopamine. J. Clin. Endocrinol. Metab. 79: 1141, 1994.
25. Van den Berghe G, de Zegher F. Anterior pituitary function during crtitical illness and dopamine treatment. Crit. Care Med. 24: 1580, 1996.
26. Jeevanandam M., Ramis L., Shamos R.F., Schiller W.R. Decreased growth hormone levels in the catabolic phase of severe iniury. Surgery 111: 495, 1992.
27. Jeffries M.K., Lee Vance M. Growth hormone and Cortisol secretion in patients with burn injury. J. Burn Care Rehabil. 13: 391, 1992.
28. Voerman H.J., Groeneveld A.B., de Boer H., Strack van Schijndel R.J.M., Nauta J.P., van der Veen E.A., Thijs L.G. Time course and variability of the endocrine and metabolic response to severe sepsis. Surgery 114: 951, 1993.
29. Melarvie S., Jeevanandam M.L., Holaday N.J., Petersen S.R. Pulsatile nature of growth hormone levels in critically ill trauma victims. Surgery 117: 402, 1995.
30. Heijligenberg R., Sauerwein H.P., Brabant G., Endertm E., Hommes M.J., Romijn J.A. Orcadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. Clin. Endocrinol. Metab. 81: 4028, 1996.
31. Casanueva F.F. Physiology of growth hormone secretion and action. Endocr. Metab. Clin. 21: 483, 1992.
32. Ghigo E. Neurotransmitter control of growth hormone secretion. In: De la Cruz L.F (Ed.). Regulation of growth hormone and somatic growth. Elsevier Science Publisher, Amsterdam 1992, p. 103.
33. Bowers C.Y. GH releasing peptides. Structure and kinetics. J. Pediatr. Endocrinol. 6: 21, 1992.
34. Van den Berghe G, de Zegher F., Bowers C.Y., Wouter P., Muller P., Soetens F., Vlasselaers D., Schetz M., Verwaest C., Lauwers P., Bouillon R. Pituitary responsiveness to GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness. Clin. Endocrinol. (Oxf.) 45: 341, 1996.
35. Van den Berghe G, de Zegher F., Veldhuis J.D., Wouters P., Awoters M., Verbruggen W., Schetz M., Verwaest C., Lauwers P., Bouillon R., Bowers C.Y. The somatotropic axis in critical illness: Effect of continuous growth hormone (GH)-releasing hormone and GH-relasing peptide-2 infusion. J. Clin. Endocrinol. Metab. 82: 590, 1997.
36. Masuda A., Shibasaki T., Hotta M., Suematsu H., Shizume K. Study on the mechanisms of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion. J. Endocrinol. Invest. 11: 297, 1988.
37. Tamai H.T., Komaki G., Matsubayashi S., Kobayashi N., Mori K., Nakagawa T., Truong M.P.M., Walter R.M., Kumagai L.F. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone (1-44)-induced GH secretion in anorexia nervosa. J. Clin. Endocrinol. Metab. 70: 738, 1990.
38. Rolla M., Andreoni A., Belliti D., Cristofani R., Ferdeghini M., Muller E.E. Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. Biol. Psych. 29: 1079, 1991.
39. Clemmons D.R., Klibanski A., Underwood L.E., Mc Arthur J.W., Ridgway E.C., Beitius I.Z., Van Wyk J.J. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J. Clin. Endocrinol. Metab. 53: 1247, 1981.
40. Ho K.Y., Veldhuis J.D., Johnson M.L., Furlanetto R. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion m man. J. Clin. Invest. 81: 968, 1988.
41. Hartman M.L., Veldhuis J.D., Johnson M.L., Lee M., Alberti K.G.M.M., Samojlik E., Thorner M.O. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal man. J. Clin. Endocrinol. Metab. 74: 757, 1992.
42. Furlanetto R.W. Insulin-like growth factor measurements in the evaluation of growth hormone secretion. Horm. Res. 33 (suppl 4): 25, 1990.
43. De Boer H., Block G.J., Poo-Snijders C., Van der Venn E.A. Diagnosis of growth hormone deficiency in adults. Lancet 343: 1645, 1994.
44. Bates A.S., Evans A.J., Jones I.P., Clayton R.N. Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin. Endocrinol. (Oxf.) 42: 425, 1995.
45. Ghigo E., Aimaretti G., Gianotti L., Bellone J., Arvat E., Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol. 134: 352, 1996.
46. Ghigo E., Arvat E., Gianotti L, Nicolosi M., Valetto M.R., Avagnina S., Bellitti D., Rolla M., Muller E.E., Camanni F. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biol. Psychol. 36: 689, 1994.
47. Moller S., Becker U. Insulin-like growth factor-I and growth hormone in chronic liver disease. Dig. Dis. 10: 239, 1992.
48. Moller S., Juul A., Becker U., Flyvbjerg A., Skakkeback N.E., Henriksen J.H. Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J. Clin. Endocrinol. Metab. 80: 1148, 1995.
49. Ross R.J.M., Chew S.L., Li L.D., Yateman M., Rodriguez-Arnao J., Holly J., Camacho-Hubner C. Expression of IGF-I and IGF-binding protein genes in cirrhotic liver. J. Endocrinol. 149: 209, 1996.
50. Friedman S.L. The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328: 1828, 1993.
51. Hartman M.L., Faria A.C.S., Vance M.L., Johnson M.L, Thorner M.O., Veldhuis J.D. Temporal structure of in vivo growth hormone secretory events in humans. Am. J. Physiol. 260: E 101, 1991.
52. Voerman H.J., van Schijndey R.J.M., Groenevel A.B.J., de Boer H., Nauta J.P., Thijs L.G. Pulsatile hormone secretion during severe sepsis: accuracy of different blood sampling regimens. Metabolism 41: 934, 1992.